ATE478950T1 - Verfahren und zusammensetzungen zum nachweis von immunantworten - Google Patents

Verfahren und zusammensetzungen zum nachweis von immunantworten

Info

Publication number
ATE478950T1
ATE478950T1 AT06759339T AT06759339T ATE478950T1 AT E478950 T1 ATE478950 T1 AT E478950T1 AT 06759339 T AT06759339 T AT 06759339T AT 06759339 T AT06759339 T AT 06759339T AT E478950 T1 ATE478950 T1 AT E478950T1
Authority
AT
Austria
Prior art keywords
compositions
methods
immune responses
detecting immune
detecting
Prior art date
Application number
AT06759339T
Other languages
English (en)
Inventor
Kelledy Manson
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE478950T1 publication Critical patent/ATE478950T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT06759339T 2005-05-05 2006-05-05 Verfahren und zusammensetzungen zum nachweis von immunantworten ATE478950T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67832905P 2005-05-05 2005-05-05
PCT/US2006/017765 WO2006122050A2 (en) 2005-05-05 2006-05-05 Methods and compositions for detecting immune responses

Publications (1)

Publication Number Publication Date
ATE478950T1 true ATE478950T1 (de) 2010-09-15

Family

ID=37076299

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06759339T ATE478950T1 (de) 2005-05-05 2006-05-05 Verfahren und zusammensetzungen zum nachweis von immunantworten

Country Status (7)

Country Link
US (2) US8703484B2 (de)
EP (1) EP1885852B1 (de)
AT (1) ATE478950T1 (de)
AU (1) AU2006244151B2 (de)
CA (1) CA2607581A1 (de)
DE (1) DE602006016433D1 (de)
WO (1) WO2006122050A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012244350B2 (en) * 2006-09-05 2013-08-15 Statens Serum Institut Ip-10 based immunological monitoring
US8026076B2 (en) * 2006-09-05 2011-09-27 Hvidovre Hospital IP-10 based immunological monitoring
RU2479848C1 (ru) * 2011-12-23 2013-04-20 Федеральное государственное бюджетное учреждение "Московский научно-исследовательский институт глазных болезней имени Гельмгольца" Министерства здравоохранения и социального развития Российской Федерации Способ прогнозирования течения увеитов, ассоциированных с ревматическими заболеваниями, у детей в условиях терапии ингибиторами фактора некроза опухоли альфа по поводу основного заболевания
WO2013172926A1 (en) * 2012-05-14 2013-11-21 Yale University Immune biomarkers and assays predictive of clinical response to immunotherapy for cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756038B1 (en) 1997-10-10 2004-06-29 The United States Of America As Represented By The Department Of Health And Human Services Agonist and antagonist peptides of carcinoembryonic antigen (CEA)
DE60235041D1 (de) 2001-11-30 2010-02-25 Us Gov Health & Human Serv Und ihre verwendung

Also Published As

Publication number Publication date
WO2006122050A3 (en) 2007-03-08
US20090023174A1 (en) 2009-01-22
CA2607581A1 (en) 2006-11-16
EP1885852B1 (de) 2010-08-25
AU2006244151A1 (en) 2006-11-16
US8703484B2 (en) 2014-04-22
DE602006016433D1 (de) 2010-10-07
AU2006244151B2 (en) 2012-05-17
WO2006122050A2 (en) 2006-11-16
EP1885852A2 (de) 2008-02-13
US20140213479A1 (en) 2014-07-31

Similar Documents

Publication Publication Date Title
EP2077821A4 (de) Zusammensetzungen und verfahren zur modulierung von immunreaktionen
LTPA2018010I1 (lt) Žmogaus anti-IL-23 antikūnai, kompozicijos, metodai ir panaudojimai
EP1799260A4 (de) Antiamyloide antikörper, zusammensetzungen, verfahren und verwendungen
EP1896073A4 (de) Anti-il-23-antikörper, zusammensetzungen, verfahren und verwendung
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
EA200702278A1 (ru) Антитела, специфичные в отношении tgf-бета 1
MX2009004883A (es) Piridil sulfoximinas multi-substituidas y su uso como insecticidas.
CY1116261T1 (el) Αντισωματα και ανοσοσυζευγματα και χρησεις αυτων
DE602005025745D1 (de) Markierte abstützmittel und verwandte verfahren
DE602005014628D1 (de) Embolie-teilchen
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
DK1838355T3 (da) Forbedrede quenching-fremgangsmåder til erytrocyt-inaktiveringsfremgangsmåde
NO20083593L (no) Anti-EphrinB2-antistoffer og fremgangsmater for anvendelse av disse
ATE544751T1 (de) Chinolinderivate als crth2-rezeptorliganden
ATE462692T1 (de) 3-amino-1-arylpropyl-indole als monoamin- wiederaufnahmehemmer
BRPI0506777A (pt) antagonistas do receptor muscarìnico da acetilcolina
NO20083609L (no) Fremgangsmater og sammensetninger for malrettet-RELT
DE602006020904D1 (de) Verfahren zum testen von antigen
EP1773386A4 (de) Vakzinzusammensetzungen und -verfahren
EP1778878A4 (de) Verfahren und zusammensetzungen zum nachweis von rhinoviren
DE602006016433D1 (de) Verfahren und zusammensetzungen zum nachweis von immunantworten
EP1907920A4 (de) Verfahren und einrichtung zum eingeben von text
DE602004023238D1 (de) Methoden zur Kultivierung von Antigen presentierenden Immunzellen
DE602006010035D1 (de) Vorrichtung zum modifizieren von brennstoff
ATE477330T1 (de) Verbesserte extraktionsverfahren und tests für futterenzyme

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties